| Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus. | |
| | |
MedLine Citation:
|
PMID: 19618992 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIM: The aim of the present study was to compare the effects of simvastatin and L-carnitine coadministration versus simvastatin monotherapy on lipid profile, lipoprotein(a) (Lp(a)) and apoprotein(a) (Apo(a)) levels in type II diabetic patients. PATIENTS/METHODS: In this double-blind, randomized clinical trial, 75 patients were assigned to one of two treatment groups for 4 months. Group A received simvastatin monotherapy; group B received L-carnitine and simvastatin. The following variables were assessed at baseline, after washout and at 1, 2, 3 and 4 months of treatment: body mass index, fasting plasma glucose, glycated hemoglobin, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, Apolipoprotein A1, Apo B, lipoprotein(a) and apoprotein(a). RESULTS: At the end of treatment in the carnitine and simvastatin combined group compared with the simvastatin alone group, we observed a significant decrease in glycemia (p < 0.001), triglycerides (p < 0.001), Apo B (p < 0.05), Lp(a) (p < 0.05), apo(a) (p < 0.05), while HDL significantly increased (p < 0.05). CONCLUSIONS: The coadministration of carnitine and simvastatin resulted in a significant reduction in Lp(a) and apo(a) and may represent a new therapeutic option in reducing plasma Lp(a) levels, LDL cholesterol and Apo B100. |
| | |
Authors:
|
Fabio Galvano; Giovanni Li Volti; Michele Malaguarnera; Teresio Avitabile; Tijana Antic; Marco Vacante; Mariano Malaguarnera |
Publication Detail:
|
Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Expert opinion on pharmacotherapy Volume: 10 ISSN: 1744-7666 ISO Abbreviation: Expert Opin Pharmacother Publication Date: 2009 Aug |
Date Detail:
|
Created Date: 2009-07-21 Completed Date: 2009-09-30 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100897346 Medline TA: Expert Opin Pharmacother Country: England |
Other Details:
|
Languages: eng Pagination: 1875-82 Citation Subset: IM |
Affiliation:
|
University of Catania, Department of Biological Chemistry, Medical Chemistry and Molecular Biology, Viale A. Doria 6, 95125 Catania, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antilipemic Agents
/
administration & dosage,
therapeutic use* Apoprotein(a) / blood Blood Glucose / drug effects Body Mass Index Carnitine / administration & dosage, therapeutic use* Cholesterol, HDL / blood Cholesterol, LDL / blood Diabetes Mellitus, Type 2 / complications* Double-Blind Method Drug Therapy, Combination Dyslipidemias / complications*, drug therapy Female Hemoglobin A, Glycosylated / drug effects Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage, therapeutic use Lipoprotein(a) / blood* Male Middle Aged Simvastatin / administration & dosage, therapeutic use* Triglycerides / blood |
| Chemical | |
Reg. No./Substance:
|
0/Antilipemic Agents; 0/Blood Glucose; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Hemoglobin A, Glycosylated; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Lipoprotein(a); 0/Triglycerides; 541-15-1/Carnitine; 79902-63-9/Simvastatin; EC 3.4.21.-/Apoprotein(a) |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The nature of psychological thresholds.
Next Document: Mometasone furoate: an inhaled glucocorticoid for the management of asthma in adults and children.